Medicinrådets protokol for vurdering vedr. alpelisib til ER+HER2- brystkræft med PIK3CA-mutation-vers. 1.0
Medicinrådets vurdering vedr. alpelisib i komb. med fulvestrant til metastatisk brystkræft-vers 1.0
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib - ScienceDirect
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization | Journal of Experimental & Clinical Cancer Research | Full Text
Development and strategies of CDK4/6 inhibitors | Future Medicinal Chemistry
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. - Abstract - Europe PMC
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies: Trends in Cancer
Frontiers | Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib - ScienceDirect
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer - ScienceDirect
CDK 4/6-hæmmer plus førstelinjebehandling forlænger overlevelsen ved metastaserende brystkræft - Dagens Medicin
Cancers | Free Full-Text | Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation - ScienceDirect
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer - ScienceDirect
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences | SpringerLink
Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors? | Future Oncology
Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies | Acta Pharmacologica Sinica
Potential combination strategies for CDK4/6 inhibitors. CDK4/6... | Download Scientific Diagram
CDK4/6 inhibition in breast cancer: current practice and future directions. - Abstract - Europe PMC
Medicinrådets lægemiddelrek. og beh.vejl. vedr. CDK46-hæmmere til ER+HER2- lokalt fremskreden eller metastatisk brystkræft
The Biological Rationale for CDK4/6 Inhibitors - YouTube
HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles | Bentham Science
Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
